共 50 条
- [1] The bispecific anti-CD3 x anti-CD155 antibody mediates T cell immunotherapy for human prostate cancerINVESTIGATIONAL NEW DRUGS, 2019, 37 (05) : 810 - 817Zhao, HuijunMa, JuanLei, TingMa, WanruZhang, Man
- [2] Anti-PSMA X Anti-CD3 Bispecific Antibody Efficiently Redirects T Cell Cytotoxicity in Castrate-resistant Prostate Cancer ModelsEUROPEAN JOURNAL OF CANCER, 2012, 48 : 98 - 98Sewell, T.Hernandez-Hoyos, G.Chenault, R. A.Wiens, J.Kumer, J.Natarajan, S.McMahan, C. J.Algate, P. A.Blankenship, J. W.
- [3] The bispecific anti-CD3 × anti-CD155 antibody mediates T cell immunotherapy for human prostate cancerInvestigational New Drugs, 2019, 37 : 810 - 817Huijun ZhaoJuan MaTing LeiWanru MaMan Zhang
- [4] Anti-SSTR2 x anti-CD3 bispecific antibody induces potent killing of human tumor cells in vitro and in mice, and stimulates target-dependent T cell activation in monkeys: A potential immunotherapy for neuroendocrine tumorsCANCER RESEARCH, 2017, 77Lee, Sung-HyungChu, Seung Y.Rashid, RumanaPhung, SherylLeung, Irene W.Muchhal, Umesh S.Moore, Gregory L.Bernett, Matthew J.Schubbert, SuzanneArdila, ConnieBonzon, ChristineFoster, PaulSzymkowski, David E.Desjarlais, John R.
- [5] Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancerANTICANCER RESEARCH, 2000, 20 (3A) : 1551 - 1555Katzenwadel, ASchleer, HGierschner, DWetterauer, UElsässer-Beile, U
- [6] Immunotherapy with Long-Lived Anti-CD38 x Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human Myeloma Cell Lines and CD38+Cells in Monkeys: A Potential Therapy for Multiple MyelomaBLOOD, 2014, 124 (21)Chu, Seung Y.Miranda, YvonnePhung, SherylChen, HsingRashid, RumanaEndo, Nancy A.Chan, Emily W.Pong, ErikBonzon, ChristineMuchhal, Umesh S.Leung, Irene W. L.Bernett, Matthew J.Moore, Gregory L.Szymkowski, David E.Desjarlais, John R.
- [7] Immunotherapy with Long-Lived Anti-CD20 x Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human B Cell Lines and of Circulating and Lymphoid B Cells in Monkeys: A Potential Therapy for B Cell Lymphomas and LeukemiasBLOOD, 2014, 124 (21)Chu, Seung Y.Lee, Sung-HyungRashid, RumanaChen, HsingChan, Emily W.Phung, SherylPong, ErikEndo, Nancy A.Miranda, YvonneBonzon, ChristineLeung, Irene W. L.Muchhal, Umesh S.Moore, Gregory L.Bernett, Matthew J.Szymkowski, David E.Desjarlais, John R.
- [8] THE ROLE OF T-CELL ACTIVATION IN ANTI-CD3 X ANTITUMOR BISPECIFIC ANTIBODY THERAPYJOURNAL OF IMMUNOLOGY, 1994, 152 (05): : 2385 - 2392WEINER, GJKOSTELNY, SAHILLSTROM, JRCOLE, MSLINK, BKWANG, SLTSO, JY
- [9] Immunotherapy with Long-Lived Anti-CD123 x Anti-CD3 Bispecific Antibodies Stimulates Potent T Cell-Mediated Killing of Human AML Cell Lines and of CD1 23+Cells in Monkeys: A Potential Therapy for Acute Myelogenous LeukemiaBLOOD, 2014, 124 (21)Chu, Seung Y.Pong, ErikChen, HsingPhung, SherylChan, Emily W.Endo, Nancy A.Rashid, RumanaBonzon, ChristineLeung, Irene W. L.Muchhal, Umesh S.Moore, Gregory L.Bernett, Matthew J.Szymkowski, David E.Desjarlais, John R.
- [10] Identification of a high-risk immunogenic prostate cancer patient subset as candidates for T-cell engager immunotherapy and the introduction of a novel albumin-fused anti-CD3 x anti-PSMA bispecific designBRITISH JOURNAL OF CANCER, 2022, 127 (12) : 2186 - 2197Glud, Eske N.Rasmussen, MartinZhang, YonghuiMandrup, Ole A.Salachan, Paul VinuBorre, MichaelSorensen, Karina DalsgaardHoward, Kenneth A.